We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ENDOTHERM and University of Heidelberg Initiate a Cooperation to Develop new Antibiotics
News

ENDOTHERM and University of Heidelberg Initiate a Cooperation to Develop new Antibiotics

ENDOTHERM and University of Heidelberg Initiate a Cooperation to Develop new Antibiotics
News

ENDOTHERM and University of Heidelberg Initiate a Cooperation to Develop new Antibiotics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ENDOTHERM and University of Heidelberg Initiate a Cooperation to Develop new Antibiotics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ENDOTHERM and Prof. Christian Klein, head of the department of medicinal chemistry at the University of Heidelberg, announce collaboration with the aim to develop new innovative antibiotics.

The project is planned to last two years and will be supported by the German ministry of economic affairs and technology by making 250.000 EURO federal funding available.

The goal of the joint research project is the development of new enzyme inhibitors to inhibit the formation of bacterial cell walls and thus act as antibiotics.

Following the principle of rational drug design, Endotherm will contribute by means of its outstanding experience in synthetic organic chemistry and modern drug discovery tools, and the group in Heidelberg will apply its existing knowledge and experience with related enzymes and will apply its drug testing technologies.

The occurrence of infectious diseases has been increased dramatically during the past 20 years, due to antibiotic resistance, global warming and globalization (intense travelling). “We regard this collaboration as an attractive chance to strengthen our position as a research driven pharmaceutical company” says Lars Kattner, CEO and coordinator of the project at Endotherm.

Advertisement